Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for controlling production of low-molecular-weight heparin

A low molecular weight heparin, low molecular weight technology, applied in the field of controlled production of low molecular weight heparin or ultra-low molecular weight heparin, can solve problems such as limiting the application of heparin

Active Publication Date: 2013-06-26
TSINGHUA UNIV
View PDF9 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the anticoagulant activity of heparin, a large amount of heparin will cause side effects such as bleeding and induction of thrombocytopenia, which greatly limits the clinical application of heparin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for controlling production of low-molecular-weight heparin
  • Method for controlling production of low-molecular-weight heparin
  • Method for controlling production of low-molecular-weight heparin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0112] The (ultra) low molecular weight heparin product obtained in Example 1 adopts high performance exclusion chromatography to measure its average molecular weight (including the weight average molecular weight M w and number average molecular weight M n ) and distribution. The gel chromatography column used is TSK Gel G3000SW, 30mm×750mm, Tosoh Co., Japan. The HPLC system used includes computer control system, peristaltic pump (LC-10ATvp), autosampler (SIL-10ADvp), ultraviolet detector (SPD-M10Avp), differential detector (RID-10A). Wherein the ultraviolet detector and the differential detector are connected in series, and the differential detector is connected behind the ultraviolet detector. The mobile phase used was pH 5.0, containing 2.84% Na by mass percentage 2 SO 4 buffer. The column temperature is 35°C, the flow rate is 0.5mL / min, and the detection wavelength of the ultraviolet detector is 235nm.

[0113] (Ultra) low molecular weight heparin molecular weight s...

Embodiment 2

[0142] Example 2 Comparison of heparinase I and heparinase III degrading heparin

[0143] Add equal amounts of heparinase I and heparinase III to the heparin solution, degrade completely at 30°C, and react until A 235 No change occurs. The product was then passed through a membrane, precipitated and evaporated to dryness under reduced pressure. The products after evaporation to dryness were subjected to molecular weight identification and anti-Xa, IIa factor activity detection, and the results are shown in Table 2. Among them, the 1# sample is the product obtained by the degradation of heparinase I, with low molecular weight and low anti-Xa and anti-IIa activities, indicating that heparanase I can cut the anticoagulant active center structure of heparin. With the prolongation of cutting time, Most of the active centers are destroyed; 2# sample is the degradation product of heparanase III, which has a larger molecular weight than 1# sample, and the important thing is that t...

Embodiment 3

[0147] Example 3 Comparison of heparinase III and heparanase III, I combined use to degrade heparin

[0148] In order to test the differences in the action sites of heparanase I and heparanase III, the following experiments were designed. First use heparanase III to degrade heparin, degrade it completely at 30°C, and react until A 235 No change occurs, then take out half of the solution, then add heparanase I to it for cleavage, keep the other half of the solution as a control, and finally evaporate the two samples to dryness under reduced pressure. The products after evaporation to dryness were subjected to molecular weight identification and anti-Xa, IIa factor activity detection, and the results are shown in Table 3. Among them, the 2# sample is the product obtained by the degradation of heparanase III (see Example 2), with a molecular weight of 8299; the 3# sample is firstly degraded completely by using heparanase III under the same conditions as in Example 5 at 30°C ,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Number average molecular weightaaaaaaaaaa
Molecular weightaaaaaaaaaa
Weight average molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention discloses a method for producing low-molecular-weight heparin or ultralow-molecular-weight heparin. According to the method, heparinases selected from more than two of heparinases I, II and III are used for degrading heparin so as to produce the low-molecular-weight heparin or ultralow-molecular-weight heparin.

Description

technical field [0001] The invention relates to a method for controlling the production of low molecular weight heparin or ultra-low molecular weight heparin. The method utilizes two or more heparinases selected from heparinase I, II and III to degrade heparin to produce low molecular weight heparin or ultra-low molecular weight heparin. Molecular weight heparin method. Background technique [0002] Heparin is a mucopolysaccharide formed by hexuronic acid (L-iduronic acid, D-glucuronic acid) and D-glucosamine sulfate by alternating 1→4 glycosidic bonds, and has a linear structure of repeating units of six or eight sugars. Chain structure, its molecular weight is between 3000-37000Da, it is used as anticoagulant reagent and antithrombotic reagent in medicine. In addition, heparin also has various biological functions such as anti-inflammation, anti-allergy, anti-virus, anti-cancer, and blood lipid regulation. However, because heparin has anticoagulant activity, a large amou...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12P19/00C12N9/88
Inventor 邢新会李晔吴敬君张翀冯权毕鲜荣
Owner TSINGHUA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com